Functional and patient-reported outcome versus in-hospital costs after traumatic acute subdural hematoma (t-ASDH): a neurosurgical paradox? by Van Dijck, J et al.
ORIGINAL ARTICLE - BRAIN TRAUMA
Functional and patient-reported outcome versus in-hospital costs
after traumatic acute subdural hematoma (t-ASDH):
a neurosurgical paradox?
Jeroen T. J. M. van Dijck1 & Thomas A. van Essen1 & Mark D. Dijkman1 & Cassidy Q. B. Mostert1 & Suzanne Polinder2 &
Wilco C. Peul1 & Godard C. W. de Ruiter1
Received: 2 January 2019 /Accepted: 12 March 2019 /Published online: 28 March 2019
# The Author(s) 2019
Abstract
Background The decisionwhether to operate or not in patients with a traumatic acute subdural hematoma (t-ASDH) can, inmany
cases, be a neurosurgical dilemma. There is a general conception that operating on severe cases leads to the survival of severely
disabled patients and is associated with relatively high medical costs. There is however little information on the quality of life of
patients after operation for t-ASDH, let alone on the cost-effectiveness.
Methods This study retrospectively investigated patient outcome and in-hospital costs for 108 consecutive patients with a t-
ASDH. Patient outcome was assessed using the Glasgow Outcome Score (GOS) and the Traumatic Brain Injury (TBI)–specific
QOLIBRI questionnaire. The in-hospital costs were calculated using the Dutch guidelines for costs calculation.
Results Out of 108 patients, 40 were classified as having sustained a mild (Glasgow Coma Scale (GCS) 13–15), 19 a moderate
(GCS 9–12), and 49 a severe (GCS 3–8) TBI. As expected, mortality rates increased with higher TBI severity (23%, 47%, and
61% respectively), whereas the chance for favorable outcome (GOS 4–5) decreased (72%, 47%, and 29%). Interestingly, the
mean QOLIBRI scores for survivors were quite similar between the TBI severity groups (61, 61, and 64). Healthcare consump-
tion and in-hospital costs increased with TBI severity. In-hospital costs were relatively high (€24,980), especially after emergency
surgery (€28,670) and when additional ICP monitoring was used (€36,580).
Conclusions Although this study confirms that outcome is often Bunfavorable^ after t-ASDH, it also shows that Bfavorable^
outcome can be achieved, even in the most severely injured patients. In-hospital treatment costs were substantial and mainly
related to TBI severity, with admission and surgery as main cost drivers. These results serve as a basis for necessary future
research focusing on the value-based cost-effectiveness of surgical treatment of patients with a t-ASDH.
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Introduction
Traumatic brain injury (TBI) is accompanied by an acute sub-
dural hematoma (t-ASDH) in around 10–20% of admitted
TBI patients [4]. Despite neurosurgical treatment, mortality
rate is high (40–60%) and outcome is often unfavorable (up
to 70%) [4, 9, 21, 31]. This frequently poses an ethical dilem-
ma for neurosurgeons, especially in the more severe cases.
Neurosurgical evacuation of the hematoma, sometimes with
additional decompressive craniectomy (DC), can save pa-
tients’ lives by decreasing intracranial pressure and preventing
secondary edema, ischemia, and inflammatory cell death, but
at the same time, it may result in the survival of severely
disabled patients [16, 23]. Alternatively, early treatment-
limiting decisions (TLD) reduce any chance of recovery and
normally result in death [35, 50]. To assist physicians in these
difficult life-or-death decisions, experts in the field have pro-
vided statements and guidelines on the preferred treatment
strategies in these patients [4, 5]. However, the overall adher-
ence to these guidelines is low, probably because the general
conception is that outcome for these patients is rather
Bunfavorable^ [6, 7, 43].
Unfortunately, in the literature, there is little information on
the health-related quality of life (HRQoL) after surgical treat-
ment of patients with a t-ASDH. Until recently, researchers
used functional indicators like the Glasgow Outcome Scale
(GOS) or generic HRQoL instruments because a TBI-
specific HRQoL instrument was not available [32, 48].
These methods however lacked the perspective of subjective
well-being and were considered to be less sensitive [46]. To
overcome these limitations, the Quality Of Life after Brain
Injury questionnaire (QOLIBRI) was developed [46]. This
TBI-specific HRQoLmeasure covers six dimensions typically
affected after TBI and provides more precise information on
quality of life [46]. It has been validated in multiple study
settings but has not been used frequently to measure outcome
after t-ASDH in clinical studies [45]. Therefore, the TBI-
specific HRQoL was investigated in addition to functional
outcome (GOS) after the surgical treatment of patients with
a t-ASDH.
Furthermore, we analyzed the in-hospital costs associated
with both conservative and different surgical treatments in
patients with a diagnosed t-ASDH. Costs for the treatment
of TBI are high and annually increasing. In the US, for exam-
ple, the national hospital costs for all subdural hematomas
were estimated to be $US1.6 billion in 2007, a 60% increase
compared to 1998 [10]. There is an increasing pressure from
governments, insurance companies, and healthcare providers
to control healthcare costs [30]. The demand for high-quality
evidence regarding the cost-effectiveness of treatments is also
seen in TBI, where it lacks and where expensive life-saving
surgical treatments can also result in a poor HRQoL [2, 22].
Because patient outcome and in-hospital costs of patients
with a t-ASDH are of great individual and societal importance,
the aim of this study is threefold: (1) assess functional out-
come and TBI-specific HRQoL, (2) calculate the in-hospital
costs, and (3) serve as a basis for future research that focusses




This retrospective cohort study was conducted at the neuro-
surgical departments of two collaborating level I trauma cen-
ters in The Netherlands (Leiden University Medical Center,
Leiden, and Haaglanden Medical Center, The Hague). The
study reports in-hospital costs and long-term HRQoL
follow-up data of patients that are part of a cohort partly used
in a separate study by the same investigators [44]. The re-
search ethics committees of Southwest Holland and Leiden
University Medical Center provided ethical approval (study
number P12.196).
Patients
All consecutive patients with TBI (2008–2012) treated by the
department of neurosurgery were identified by screening the
hospital registration system. In addition, the national trauma
registry was checked for potential missed inclusions.
Inclusion criteria were (1) closed head injury due to a traumat-
ic event, (2) direct presentation to the emergency department
of a referring or study hospital following trauma, (3) a
hyperdense, crescent-shaped lesion on CT, indicative of an
ASDH, and (4) age ≥ 16 years. To pursue a homogenous pa-
tient cohort, patients were excluded in case of non-survivable
extracranial injuries, a non-traumatic ASDH, when the ASDH
was accompanied by concomitant intracranial lesions (i.e.,
intracerebral hematoma or epidural hematoma) requiring im-
mediate surgical management and when the ASDH was sec-
ondary to an earlier procedure or penetrating brain injury.
Eligibility, the QOLIBRI questionnaire was assessed based
on exclusion criteria: GOS ≤ 3, inability to provide informed
consent and inability to understand, cooperate, and answer
QOLIBRI questions. TBI severity was defined according to
the commonly used Glasgow Coma Score scale (GCS) cate-
gories (GCS13–15, mild; GCS 9–12, moderate; GCS 3–8,
severe) [39]. In addition, a subgroup of patients with a very
severe TBI (vs-TBI), represented by a GCS of 3–5, was
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analyzed. The first GCS score documented at the emergency
room (ER) was used and in case of intubation and/or sedation,
the last score before intubation and/or sedation was used.
Clinical and follow-up data
Data was collected independently by two authors in a
predefined database using electronic or paper patient records.
It encompassed demographics, patient- and trauma-specific
information, and pre- and in-hospital parameters including
medical/surgical interventions and length of stay. Non-ICU
admission included admission on the ward and medium care.
Focal neurologic symptoms included paresis, aphasia, or cra-
nial nerve deficit. Pupils were defined as abnormal when at
least one pupil was unresponsive to light upon arrival in the
emergency room. CT characteristics were assessed from the
first CTscan. Outcome data included in-hospital mortality and
Glasgow Outcome Score (GOS) dichotomized in favorable
(GOS 4–5) and unfavorable (GOS 1–3) outcome obtained
from discharge or outpatient clinic letters 3–9 months after
trauma [48]. To determine the TBI-specific HRQoL, we used
the postal Quality of Life after Brain Injury (QOLIBRI) ques-
tionnaire. After receiving ethical approval to approach pa-
tients, we obtained informed consent and asked patients to
complete and return the questionnaire 2 to 6 years after trau-
ma. Mortality at this time point was also noted. The QOLIBRI
is a comprehensive 37-item questionnaire investigating six
dimensions that are typically affected after TBI [46]. Patients
rate their (dis)satisfaction (1–5 scale) on six subscales
representing the dimensions: cognition, self, daily life and
autonomy, social relationships, emotions, and physical prob-
lems. Scores are transformed to total scores ranging from 0
(worst possible quality of life) to 100 (best possible quality of
life) [46]. A score lower than 60 is believed to represent a low
or impaired HRQoL [49]. In case patients did not return the
questionnaire, the investigators attempted a telephone inter-
view, or family members were asked to assist in completing
the forms. In addition, the reason for not returning (e.g., death,
persistent unresponsive state) the questionnaire was collected
at this time point.
Cost data
Cost data analysis was performed from a healthcare provider
perspective and focused on in-hospital healthcare costs. The
Dutch National Health Care Institute guidelines for healthcare
cost calculation were followed [14]. First, data on healthcare
consumption were collected from electronic patient records
and recorded in a predefined cost assessment database. Units
were counted in five main categories: (1) admission, including
length of stay (LOS) in (non-)ICU with consultations, (2)
surgical interventions, (3) imaging, (4) laboratory, including
blood products, and (5) others, including transportation and
outpatient visits. Since this study focused on in-hospital acute
healthcare costs, only post-discharge costs associated with re-
admissions and outpatient clinic visits related to the initial
trauma were included. Second, as hospital-specific cost prices
were not available for external research purposes, units were
valued by using external sources in accordancewith the guide-
lines [14]. Some units were valued using the reference prices
from the guideline, being cost prices based on large patient
cohorts [14]. The use of these prices is recommended for costs
research and preferred for cost outcome interpretation and
generalization because prices are non-site-specific [14, 37].
Units that were not available in the guidelines were valued
using the maximum amount per unit that healthcare providers
are allowed to charge according to the The Netherlands
Healthcare Authority (NZa), an autonomous administrative
authority falling under the Dutch Ministry of Health,
Welfare and Sport [29]. The remaining units were valued by
using their average national price based on declared fees in-
cluding hospital costs and physicians’ fees [28]. A detailed
overview of all used unit costs and corresponding sources
can be found in Supplement 1.
Third, we corrected all unit costs expressed in different
base years to 2012 EUROusing the national general consumer
price index (CBS). This year was chosen because it was the
last year of patient inclusion. And finally, to calculate in-
hospital costs, all counted units were multiplied with its cor-
responding price and rounded to the nearest ten euros. No
discounting of costs was deemed necessary. In January
2012, one euro equaled $1.28.
Statistical analysis
Baseline data were presented as absolute numbers and
percentages. Continues variables, like costs and LOS,
were presented as mean ± standard deviation unless
stated otherwise. Subgroups were made based on age, TBI
severity, pupillary abnormalities, surgical intervention, and
outcome. Comparison between groups was done by using an
independent t test. A p value of < 0.05 was considered statis-
tically significant. All analyses were performed using IBM’s
statistical package for social sciences version 23 (SPSS).
Figures were designed with GraphPad Prism version 7.02.
Results
Out of 294 initially identified TBI patients, 140 patients did
not have a t-ASDH, six had penetrating injuries, nine required
surgery for concomitant intracranial lesions, and 31 patients
were excluded following the other exclusion criteria.
Ultimately, 108 patients were included in this study. The final
study cohort included 57 males (52.8%) and had a mean age
of 65 years (range 18–91) (Table 1). Most ASDH patients
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(N = 49) sustained a severe TBI (s-TBI) followed by mild
(N = 40) and moderate TBI (N = 19). Of patients with s-TBI,
22 were classified as having sustained a vs-TBI. A quarter of
all patients had at least one non-reactive pupil (N = 27) and
38.9% had focal neurologic symptoms. A concomitant intra-
cranial hematoma that did not require surgical intervention
was present in 44.4% of patients and 11.1% had clinically
relevant extracranial injuries. Neurosurgical intervention was
performed in 90 patients (60 craniotomies, 29 decompressive
craniectomies, and one burr hole) and an ICP monitoring de-
vice was placed in 40 patients. Most of the conservatively
treated patients (N = 18) were classified as mild TBI (83%).
Patient outcome
In-hospital mortality was 38% and mortality increased to 44%
during follow-up (mean 37 ± 17 months). Mortality ranged
from 23% for initial mild-TBI to 64% for patients with vs-
TBI (Table 2). Favorable outcome (GOS 4–5) was seen in
47% of all patients, 72% of patients with mild-TBI, and in
23% of patients with vs-TBI (Fig. 1). High rates of unfavor-
able outcome (GOS 1–3) were seen in patients with a GCS of
3 (90%), ICP monitoring (75%), decompressive craniectomy
(72%), pupillary abnormalities (70%), and age < 65 (63%).
Twenty-five patients (42% of survivors) returned a com-
pleted QOLIBRI questionnaire. Return percentages were low-
er for patients with higher initial severity scores (9% for vs-
TBI and 35% for mild TBI) and lower for patients with worse
functional outcome (4% for GOS 1–3 vs. 46% for GOS 4–5).
Mean QOLIBRI scores however were rather similar between
TBI severity groups (61 ± 25 for s-TBI and 64 ± 24 for mild
TBI). Patients with post-trauma pupillary abnormalities
(49.8), ICP monitoring (55.1), and patients with unfavorable
outcome (GOS 1–3) (50.5) showed mean QOLIBRI scores
suggesting an impaired HRQoL. Patients receiving a craniot-
omy showed better scores (68.4) than patients receiving a
decompressive craniectomy (53.2).
Healthcare consumption
Patients with vs-TBI had a significantly longer ICU LOS than
patients with mild TBI (6 vs. 2 days, P < 0.001) (Table 3).
Mean LOS for non-ICU admissions was longest for patients
with moderate TBI (16 days), followed by 12 and 9 days for
patients with vs-TBI and mild TBI. All vs-TBI and 98% of s-
TBI patients received cranial surgery, compared to 89.5% of
moderate and 62.5% of mild TBI patients. ICP monitoring
was most frequently used in patients with vs-TBI and s-TBI
(63.6% and 57.1%), but also in 12.5% of patients with mild
TBI. ICP monitoring was associated with significantly longer
ICU and non-ICU LOS compared to non-ICP-monitoring.
Table 1 Patient cohort information
Number of patients 108





Motor vehicle accident 12 (11.1)
Fall from bike 12 (11.1)
Other 21 (19.4)
TBI severity
Very severe (GCS3–5) 22 (20.4)
Severe (GCS3–8) 49 (45.4)
Moderate (GCS9–12) 19 (17.6)
Mild (GCS13–15) 40 (37.0)
Clinical parameters
GCS score 9.63 ± 4.3
Pupil abnormality* 27 (26.7)
Focal neurologic symptoms 42 (38.9)
Major extracranial injury 12 (11.1)
CT parameters
Thickness (mm) 13.6 ± 6.1
Midline shift (mm) 11.4 ± 6.6
Concomitant lesion 48 (44.4)
Basal cisterns compressed 39 (36.1)
Treatment
Conservative 18 (16.7)
Emergent surgical intervention: 90 (83.3)
Craniotomy − 60 (55.6)
Decompressive craniectomy (DC) − 29 (26.9)
ICP monitoring − 40 (37.0)
In-hospital mortality 41 (37.9)
Functional outcome
GOS1–3 (unfavorable) 56 (51.9)
GOS4–5 (favorable) 50 (46.3)
Missing GOS 2 (1.9)
QOLIBRI response
FU time, months 46 ± 16
Yes 25 (23.1)
No (died; too disabled) 53 (48; 5)
No, other 30 (27.8)
Table 1 provides general information about the patient cohort. Legend: N
(%) or mean ± SD, unless stated otherwise
SD, standard deviation; GCS, Glasgow Coma Score; CT, computed to-
mography; DC, decompressive craniectomy; ICP, intracranial pressure;
GOS, Glasgow Outcome Score; QOLIBRI, quality of life after brain in-
jury; FU, follow-up
*At least one pupil unresponsive to light upon arrival in the emergency
room (missing for seven patients)
878 Acta Neurochir (2019) 161:875–884
Healthcare costs
Mean in-hospital costs were €24,980 per patient and primarily
the result of costs related to admission (€14,980) and surgical
intervention (€6890). Mean in-hospital costs were significant-
ly higher for vs-TBI (€30,230), s-TBI (€29,660), and moder-
ate TBI (€27,650) subgroups compared to the mild TBI
(€17,980) subgroup (P < 0.05) (Table 3). For these severity
subgroups, mean costs specifically related to ICU admission
were €13,230, €13,150, €7550, and €5460 respectively
(Fig. 2). Patients’ healthcare utilization was more expensive
after surgical intervention than conservative treatment
(€28,670 vs. €6520). Patients with a decompressive
craniectomy showed the highest cost specifically related to
surgery. Patients with additional ICP monitoring (€36,580)
showed highest total costs, of which 64% was related to ad-
mission. A lower initial GCS and pupillary abnormalities
show an increase in patient LOS and in-hospital costs, except
for patients with a GCS of 3. Other characteristics associated
with significantly increased total costs were: age < 65, a
concomitant intracranial hematoma that did not require
surgical intervention, presence of pupillary abnormalities, and
unfavorable outcome.
Five patients (23%) from the vs-TBI subgroup achieved
favorable outcome (GOS4–5) at mean in-hospital costs of
€132,610 per patient. Mean costs for patients achieving favor-
able outcome were €103,790 for s-TBI patients (N = 14; 29%),
Table 2 Patient outcome
Patient category N N (%) death ^ N (%) GOS1–3 N (%) returned
QOLIBRI#
QOLIBRI score QOLIBRI follow-up
(months)
All patients 108 48 (44) 56 (53) 25 (23) 62.8 ± 23.5 37 ± 17
Age ≥ 65 65 21 (32) 29 (45) 16 (25) 66.8 ± 22.1 38 ± 18
Age < 65 43 19 (44) 27 (63) 9 (21) 55.7 ± 25.6 35 ± 16
GCS 3 10 7 (70) 9 (90) 0 N/A N/A
GCS 3–5 22 14 (64) 17 (77) 2 (9) 66.0 ± 7.07 13 ± 2
GCS 3–8 49 30 (61) 35 (71) 7 (14) 61.4 ± 24.8 34 ± 19
GCS 9–12 19 9 (47) 10 (53) 4 (21) 61.0 ± 25.5 50 ± 21
GCS 13–15 40 9 (23) 11 (28) 14 (35) 64.0 ± 24.1 35 ± 14
Pupillary abnormality 27 15 (56) 19 (70) 5 (19) 49.8 ± 19.4 47 ± 23
No abnormalities* 74 29 (39) 32 (43) 18 (24) 64.5 ± 24.6 32 ± 13
Emergency surgery
No 18 3 (17) 3 (17) 4 (22) 56.3 ± 28.6 33 ± 15
Craniotomy 60 26 (43) 32 (53) 15 (25) 68.4 ± 21.0 36 ± 17
Decompressive craniectomy 29 18 (62) 21 (72) 6 (21) 53.2 ± 26.3 42 ± 21
ICP monitoring 40 20 (50) 30 (75) 9 (23) 55.1 ± 20.4 36 ± 24
No ICP monitoring 68 28 (41) 26 (38) 16 (24) 67.1 ± 24.7 37 ± 13
Outcome (GOS)
Favorable 50 4 (8) N/A 23 (46) 63.9 ± 23.3 37 ± 17
Unfavorable 56 42 (75) 56 (100) 2 (4) 37 ± 25
Missing 2 50.5 ± 2.1
Table 2 provides an overview of mortality, functional outcome and health related quality of life per subgroup. Legend: results presented as number (row
percentage) and mean ± SD
# The response rate is reported as percentage of survivors from the specific category
*Pupillary abnormality information was missing for seven patients
^Mortality at time of QOLIBRI follow-up
LOS, length of stay; GCS, Glasgow Coma Score; ICP, intracranial pressure; QOLIBRI, quality of life after brain injury;M, months; N/A, not applicable
Fig. 1 Functional outcome (favorable GOS 4–5, unfavorable GOS 1–3)
and TBI-specific health-related quality of life (QOLIBRI) for all patients
and for severity subgroups
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€58,150 for moderate TBI patients (N = 9; 47%), and €24,800
per mild-TBI patient (N = 29; 72%). Mean in-hospital costs
were highest (€246,920) for one patient from the GCS = 3 sub-
group (N = 10) that reached favorable outcome.
Discussion
BFavorable^ outcome with a good HRQoLwas achieved in an
important quarter proportion of the seemingly most severely
injured patients. This retrospective cohort study, however, also
shows high rates of mortality and so-called unfavorable out-
come in patients with a t-ASDH and relatively high healthcare
consumption and in-hospital costs. These costs increased with
higher injury severity scores and in patients with surgical in-
tervention. The majority of costs were related to (ICU) admis-
sion and surgical intervention. According to the investigators,
this study shows a trend that surgical treatment of t-ASDH can
realize favorable outcome in s-TBI at for society acceptable
in-hospital costs.
Patient outcome
Accurate comparison of the reported patient outcome results
with literature is challenging because outcome in TBI is high-
ly variable and dependent on patient characteristics, circum-
stances, social context, and treatment [7, 9, 13, 21, 31].
Nonetheless, the important result that even the most severely
injured TBI patients can, although a small number, achieve
favorable outcome (GOS) and good quality of life (QOLIBRI)
is supported by recent literature [36, 42].
Our QOLIBRI results are not applicable to study patients
with a cognitive dysfunction and/or impaired self-awareness
that is too severe to complete the questionnaire. The unmea-
sured HRQoL of these patients might have negatively
Table 3 Length of stay and in-hospital costs
Patient category N ICU LOS Non-ICU LOS Total costs (€) Admission costs Surgery costs
All patients 108 4 ± 4 11 ± 14 24,980 ± 17,060 14,980 ± 14,000 6890 ± 4270
Age ≥ 65 65 3 ± 3 10 ± 12 20,820 ± 13,480 11,750 ± 10,670 6150 ± 4040
Age < 65 43 6 ± 5 12 ± 16 31,260 ± 19,930 19,850 ± 16,890 8020 ± 4410
GCS 3 10 3 ± 3 11 ± 19 24,690 ± 18,020 13,720 ± 16,310 7940 ± 2340
GCS 3–5 22 6 ± 4 12 ± 17 30,230 ± 16,370 19,110 ± 14,910 7710 ± 1750
GCS 3–8 49 6 ± 5 11 ± 14 29,660 ± 17,870 18,780 ± 15,890 7520 ± 2200
GCS 9–12 19 3 ± 3 16 ± 20 27,650 ± 15,780 15,120 ± 12,600 9230 ± 5470
GCS 13–15 40 2 ± 4 9 ± 8 17,980 ± 14,460 10,250 ± 10,610 5010 ± 4840
Pupillary abnormality 27 7 ± 5 13 ± 14 33,430 ± 18,330 22,480 ± 16,850 7510 ± 1600
No abnormalities 74 3 ± 4 11 ± 14 22,220 ± 16,110 12,590 ± 12,120 6690 ± 4940
Emergency surgery 90 5 ± 5 12 ± 15 28,670 ± 16,230 17,120 ± 14,290 8270 ± 3220
No 18 1 ± 2 4 ± 5 6520 ± 4320 4240 ± 4160 0
Craniotomy 60 4 ± 4 12 ± 14 26,400 ± 14,680 16,040 ± 12,790 7310 ± 3060
DC 29 6 ± 5 11 ± 16 33,140 ± 19,070 19,950 ± 16,980 9550 ± 3790
ICP monitoring 40 7 ± 5 15 ± 16 36,580 ± 16,650 23,420 ± 15,260 9340 ± 3730
No ICP monitoring 68 2 ± 3 9 ± 12 18,150 ± 13,250 10,010 ± 10,480 5460 ± 3920
Outcome
Favorable* 50 3 ± 4 11 ± 10 20,430 ± 16,540 12,320 ± 13,170 5270 ± 3910
Unfavorable 56 5 ± 5 11 ± 16 29,230 ± 16,850 17,650 ± 14,490 8230 ± 4100
Dead at discharge 41 5 ± 4 6 ± 10 25,340 ± 12,450 13,890 ± 10,070 8180 ± 3770
Table 3 provides an overview of length of stay and in-hospital costs per subgroup. In-hospital costs are divided between costs related to admission and
surgical intervention. Mean ± SD; all costs in € and LOS in days
*GOS outcomes not available for two patients
N, number; LOS, length of stay; GCS, Glasgow Coma Score; ICU, Intensive Care Unit; DC, decompressive craniectomy; ICP, intracranial pressure
Fig. 2 Mean and total in-hospital costs for all patients and for severity
subgroups. Also, a distinction has been made between investigated cost
categories to show their share to the total in-hospital costs
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influenced the reported HRQoL per TBI severity group. The
applicability of the QOLIBRI for all patients with TBI remains
unclear since it has only been validated in patients without
substantial post-traumatic cognitive restraints [45]. Proxy
completion is impossible for many QOLIBRI items and mis-
ses the essence of measuring the Bself-perceived^ HRQoL. It
also remains unclear whether the cut-off point of 60 is satis-
fying for quantifying a good HRQoL [49]. Therefore, validity
should be confirmed for patients with TBI-associated
persisting cognitive restraints or suitable new (HRQoL) mea-
surement options need to be developed.
In contrast to earlier published reports on t-ASDH, the mean
cohort age of 65 years was relatively high, but in accordance
with changing TBI epidemiology [25]. Also, a large number of
patients had an initial low GCS and/or pupillary abnormalities.
These three factors are known to negatively influence outcome
and sometimes these patients are even considered unsalvage-
able [9, 13, 42]. Nevertheless, neurosurgical intervention was
performed in up to 98% of patients with s-TBI. This percentage
is high compared to other studies, but seems rational, since
neurosurgical evacuation of the hematoma and/or DC can be
lifesaving and prevent secondary injury by decreasing ICP [9,
20, 21, 23]. The high percentage can also be explained by the
specific selection of patients with a t-ASDH where neurosurgi-
cal consultation was considered necessary, suggesting a higher
vulnerability. Although the present study did not evaluate treat-
ment effectiveness, a separate analysis by the authors seemed to
support themore aggressive approach [44]. Even so, superiority
between hematoma evacuation or DC remains unknown and no
clinical trial has proven primary DC to be effective in improv-
ing patient outcome [17, 31]. Surgical intervention is even con-
troversial because patients may survive with Bunacceptable^
severe disabilities with an accompanying high burden on prox-
ies and society [16]. This is fundamental in neurosurgical treat-
ment decision-making and as a result, a Bsurgical^ treatment
strategy as seen in this study, which follows the guidelines, is
not a standard day-to-day care in all hospitals [9, 20, 43, 44].
Instead, treatment-limiting decisions in s-TBI are common
in some countries and often made within the first 2 days after
trauma [35, 50]. Limiting treatment offers no serious chance
of recovery and regularly results in quick death [35, 50]. We
acknowledge that these decisions are sometimes inevitable
and could be in a patients’ best interest when there is no
realistic chance to achieve a Bfavorable^ outcome. But what
can be considered a favorable or an unfavorable outcome after
s-TBI and vs-TBI?
Therefore, according to the investigators, it would be cata-
strophic to limit or withhold treatment in patients that could
have still benefitted from it. Physicians should be careful in
making early treatment limiting decisions when there is still
uncertainty, because uncertainty implies a possibility for favor-
able outcome. Unfortunately, uncertainty in predicting who
will benefit from what treatment is very common. There is
substantial variation in the perception of neurologic prognosis
among physicians and high treatment variation [7, 41, 43]. In
line with some literature, we believe that treatment-limiting
decisions in the early phase cannot be justified because prog-
nostication is not yet accurate enough [12]. In a later stage,
when clinical and neurological improvements remain absent,
further treatment might be considered futile with more certain-
ty. Then, treatment-limiting decisions should be discussed with
all involved healthcare professionals and proxies.
Healthcare consumption and in-hospital costs
The costs related to admission and surgical intervention cost
categories appeared to be the most important contributors to
the reported in-hospital costs. In literature, costs related to ICU
admission were also high and in-hospital costs also increased
with higher injury and TBI severity (defined by GCS), ICP
monitoring, and surgical intervention [3, 8, 27, 34, 38]. The
surprisingly lower LOS and in-hospital costs for elderly pa-
tients in this study could be explained by the fact that only
33.8% of elderly patients was classified as severe, compared
to 62.8% of patients younger than 65.
Overall, the reported healthcare consumption and in-
hospital costs seem to be quite similar to literature [18, 34,
38]. However, comparison was difficult due to substantial
methodological variation and often inadequate methodology
of available TBI cost studies [2, 22]. The detailed calculation
of healthcare consumption and in-hospital costs is an impor-
tant strength of this study. The electronic patient file setup
reduced the risk to a minimum that unregistered activities
contributed to an underestimation of in-hospital resource uti-
lization. Still, the numbers in this study are an enormous un-
derestimation of the total healthcare consumption and total
costs associated with t-ASDH and TBI because the majority
of costs are indirect and arise after hospital discharge [11, 34,
40]. Also, interpretation and generalization of the results
should be done carefully since included patients represent a
specific selection of patients with a t-ASDH with a suspected
higher vulnerability, where patients with a concomitant hema-
toma requiring surgical intervention were excluded. Also, the
inevitable presence of coexisting injuries causes that results
are not solely attributable to TBI.
Despite these remarks, the reported costs give rise to the
question whether or not the in-hospital costs may be justified
by the achieved outcome. The mean in-hospital costs per pa-
tient appear to be acceptable for all TBI severity groups.
However, when adding up the in-hospital costs that are made
to have one patient achieve a favorable outcome, especially
for the most severely injured patients appear to be expensive.
Unfortunately, true cost-effectiveness could not be established
in this study, and because there is no consensus in literature,
additional research is needed to establish cost-effectiveness
and justification of expenses in TBI care [1, 15, 26, 47].
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Future perspective
Future research should establish long-term outcome of ASDH
patients after different treatment strategies. A high-quality
cost-effectiveness research should incorporate a long-term fol-
low-up and should use accurate resource utilization and cost
price information [19, 33]. Future research should also explore
the societal impact of t-ASDH, including productivity loss of
both patients and proxies. Investigators should aim at compa-
rability and generalizability by using common data points and
guideline recommendations [24]. Ultimately, researchers
should explore what health states and associated costs can
be considered Bacceptable^ to patients, proxies, and society.
Conclusions
Although outcome was often Bunfavorable,^ several of the
most severely injured patients, often even considered unsal-
vageable, achieved favorable outcome on both GOS and
QOLIBRI. Associated hospital costs were relatively high, es-
pecially for the most severely injured patients, but may be
justified considering the realized favorable outcome in part
of these patients. Patients should not prematurely be consid-
ered unsalvageable and adequate (surgical) therapy should not
be withheld in the acute phase. More research is necessary to
establish the cost-effectiveness of treatment strategies for pa-
tients with a t-ASDH.
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